Report Title - The report is titled "Public Offering Infrastructure REITs Weekly Report" [1] Report's Core View - In the week from August 25 to August 29, 2025, the REITs weighted index rose 1.20% to 101.29 points. Different types of REITs showed varied performance in terms of price changes, trading volume, turnover rate, and valuation. There are also 11 REITs in the exchange acceptance stage and 2 in the approved - to - be - listed state as of August 29, 2025 [2][5] Industry Investment Rating - No industry investment rating is provided in the report Summary by Relevant Catalog Secondary Market Performance - **Overall Index Performance**: The REITs weighted index rose 1.20%, while the CSI All - Share Index rose 1.84%, the CSI Convertible Bond Index fell 2.58%, the ChinaBond Net Price Index rose 0.05%, the London Gold Spot rose 1.32%, and the weighted crude oil varieties fell 1.44%. The order of performance from high to low is stocks > gold > REITs > pure bonds > crude oil > convertible bonds [2] - **Underlying Asset Type Performance**: This week, the property - right type fell 2.07% to 112.64, and the franchise type fell 1.08% to 84.97. By industry type, consumer - type REITs rose 2.21%, ecological and environmental - protection type rose 2.03%, and so on. The order of weekly return performance from high to low is consumer - type > ecological and environmental - protection type > affordable rental housing type > warehousing and logistics type > data center > industrial park type > highway type > energy type [2] - **Top Performers**: The top three REITs in terms of weekly increase are Guotai Junan Jinan Energy Heating REIT (5.70%), AVIC Yishang Warehousing and Logistics REIT (4.29%), and Jiashi Wumei Consumption REIT (4.22%). In terms of trading volume, CICC Hubei Ketou Optics Valley REIT, Huaxia Hefei High - tech REIT, and Huaxia Fund China Resources Youchao REIT led with 0.29 billion shares, 0.28 billion shares, and 0.24 billion shares respectively. In terms of turnover rate, Huatai Nanjing Jianye REIT, Huatai Baowan Logistics REIT, and Huaxia Huadian Clean Energy REIT had higher turnover rates of 14.75%, 12.66%, and 9.85% respectively [2][3][12] Secondary Market Valuation - **P/FFO Indicator**: This week, the dynamic P/FFO of many REITs such as Hongtu Innovation Yantian Port REIT, CICC GLP REIT is lower than the average of their respective industry types [4][19] - **P/NAV Indicator**: The top three REITs with lower valuation quantiles and showing an undervalued state are Huaxia Huadian Clean Energy REIT, Huaxia Yuexiu REIT, and CICC Hubei Ketou Optics Valley REIT [4][19] Primary Market Tracking - As of August 29, 2025, there are 11 REIT products still in the exchange acceptance stage and 2 in the approved - to - be - listed state [5] Market Correlation Statistics - **REITs and Major Asset Correlation**: This week, the correlation coefficient between REITs and the Shanghai Composite Index is the highest at 0.20. The correlation coefficients with other major assets such as the CSI 300, ChiNext Index also vary [23][24]

Report Industry Investment Rating - No information provided Core Viewpoints - This week, the three strategies jointly held 22 convertible bonds, including Pufa Convertible Bond, Muyuan Convertible Bond, 23 Hope E1, etc. The option strategy maintained low turnover with few new targets, while the sub - low - price strategy had increased turnover recently, possibly due to the high enthusiasm in the equity market [1]. - The model recommends the technology sector at the industry level, driven mainly by the momentum factor, consistent with previous reports. The recommended industries include communication, electronics, computer, power equipment, and household appliances, with a marginal increase in the computer factor score and a decline in the household appliance factor score but still within the recommended range [1]. Summary by Related Catalogs Strategy Performance - The sub - low - price strategy rose 2.72% last week, with an excess return of 0.07% compared to the Wind Convertible Bond Low - Price Index. It has risen 18.32% this year, with an excess return of 1.01% compared to the benchmark [10]. - The option strategy rose 3.21% last week, with an excess return of 0.55% compared to the Wind Convertible Bond Low - Price Index. It has risen 20.66% this year, with an excess return of 2.93% compared to the benchmark [10]. - The double - low enhancement strategy rose 3.08% last week, with an excess return of 1.16% compared to the Wind Convertible Bond Double - Low Index. It has risen 24.14% this year, with an excess return of 9.67% compared to the benchmark [10]. - The industry rotation strategy rose 3.21% last week, with an excess return of 1.30% compared to the Wind Convertible Bond Double - Low Index. It has risen 18.37% this year [10]. Risk - Return Characteristics (Last Year) - The sub - low - price strategy has an annualized return of 33.58%, a Calmar ratio of 5.58, and a maximum drawdown of 6.02% [12]. - The option strategy has an annualized return of 33.20%, a Calmar ratio of 7.09, and a maximum drawdown of 4.68% [12]. - The double - low enhancement strategy has an annualized return of 45.33%, a Calmar ratio of 5.92, and a maximum drawdown of 7.65%, with an annualized excess return of 13.60% [12]. - The industry rotation strategy has an annualized return of 43.77%, a Calmar ratio of 6.61, and a maximum drawdown of 6.62%, with an annualized excess return of 12.22% [12]. Factor Back - test Results - For the sub - low - price strategy, the priceavg factor has a weight of 100%, an IC mean of - 3.44%, an IC standard deviation of 17.53%, an ICIR of - 19.63%, an IC>0 frequency of 35.25%, and a p - Value of 0.01% [20]. - For the option strategy, the amplitude_mean_6m factor has a weight of 100%, an IC mean of - 4.41%, an IC standard deviation of 19.36%, an ICIR of - 22.80%, an IC>0 frequency of 31.42%, and a p - Value of 0.00% [20]. - For the double - low enhancement strategy, multiple factors are used with different weights. For example, the impliedvol diff1 3m, MaxPricePremium, pricechangediff di ff1 1w, priceavg priceavg, stkratio diff1 1w, Amihud diff1 3m, and MaxPricePremium factors each have a 20% or 25% weight. The pricechangediff di ff1 1w factor has an IC mean of - 3.02%, an IC standard deviation of 9.17%, an ICIR of - 32.92%, an IC>0 frequency of 24.90%, and a p - Value of 0.00% [20]. - For the industry rotation strategy, factors like diff1 1m, pricechangediff_mean 2w, and stkratio diff1 1m are used with 25% weights. The diff1 1m factor has an IC mean of - 3.29%, an IC standard deviation of 23.44%, an ICIR of - 14.04%, an IC>0 frequency of 42.31%, and a p - Value of 0.45% [20].

Exchange Rate Trends - The RMB/USD exchange rate has shown a fluctuating upward trend since the beginning of the year, with a slight appreciation in early 2023 due to a weaker dollar, followed by a rapid depreciation in April due to tariff concerns, and a return to appreciation from May onwards[2] - As of late August, the RMB has entered a strong appreciation phase, with the onshore and offshore rates converging towards the 7.0 level, indicating support from both fundamental and policy factors[2][5] Key Drivers of RMB Appreciation - The narrowing of the China-US 10-year Treasury yield spread by nearly 50 basis points over the past three months has provided a basis for recent RMB appreciation, driven by a mild increase in China's risk-free interest rates and a decline in US Treasury yields[7] - Changes in policy risk premiums have favored the RMB, as rising uncertainty in US fiscal and monetary policies contrasts with China's efforts to reduce sovereign risk premiums through reforms[6][14] - The long-standing undervaluation of the RMB is changing, with IMF data indicating that 1 USD has a purchasing power equivalent to 3.4 RMB, suggesting the current exchange rate is undervalued by over 50%[17][20] Catalysts for Recent Appreciation - The People's Bank of China (PBOC) has released strong appreciation expectations through its midpoint rate, influenced by geopolitical negotiations and domestic stability considerations[3][31] - The bullish trend in the A-share market, with the Shanghai Composite Index rising over 8% and the ChiNext Index over 20% in August, has led to increased foreign investment and demand for RMB[40] Future Outlook - The weak dollar environment is expected to continue supporting RMB appreciation, but factors such as weak export expectations and the need for domestic demand recovery suggest a stable appreciation pace is more beneficial for fundamental recovery[47] - The importance of the RMB against a basket of currencies is anticipated to rise, reflecting the need for a more balanced exchange rate strategy[49]

Report Title - "Number Analysis of Public Offering Pure Bond and Hybrid Asset Strategy Funds' 2025 Semi-Annual Report - Institutions Increase Allocation to 'Fixed Income +', and Allocate More Growth-Oriented Equity Assets" [1] Report Date - September 2, 2025 [2] Core View - The report analyzes the performance, asset allocation, and institutional holding changes of various types of bond and hybrid asset strategy funds, showing that institutions are increasing their allocation to 'fixed income +' funds and shifting their equity asset allocation towards growth directions. Summary by Fund Type Short-Term Pure Bond Funds - Multiple funds are listed, such as Great Wall Short Bond A (007194.OF) with a scale of 3.2686 billion yuan, an institutional holding of 1.7147 billion shares, and an institutional increase of 0.5179 billion shares. Its 1-year return is 2.91% (ranked 22/347), and the 3-year return is 3.81% (ranked 2/278) [21]. - Another example is Boshi Credit Preferred A (009271.OF) with a scale of 2.0333 billion yuan, an institutional holding of 1.0058 billion shares, and an institutional increase of 0.7677 billion shares. Its 1-year return is 2.24% (ranked 127/347), and the 3-year return is 3.37% (ranked 13/278) [23]. Medium and Long-Term Pure Bond Funds - For instance, Bank of China Fenghe Regular Open (004722.OF) has a scale of 4.8366 billion yuan, an institutional holding of 4.3551 billion shares, and no institutional increase. Its 1-year return is 2.68% (ranked 1287/1965), and the 3-year return is 3.28% (ranked 841/1509) [21]. - Guoshou Anbao Tai'an Pure Bond (010232.OF) has a scale of 2.401 billion yuan, an institutional holding of 2.2246 billion shares, and an institutional increase of 0.2758 billion shares. Its 1-year return is 3.93% (ranked 315/1965), and the 3-year return is 4.18% (ranked 152/1509) [21]. Mixed Bond - Type I Funds - Invesco Great Wall Jingtai Pure Profit A (007562.OF) has a scale of 1.9143 billion yuan, an institutional holding of 1.1324 billion shares, and an institutional increase of 0.4631 billion shares. Its 1-year return is 5.32%, and the 3-year return is 4.33% (ranked 43/329) [21]. - E Fund Enhanced Return A (110017.OF) has a scale of 3.1526 billion yuan, an institutional holding of 0.8182 billion shares, and an institutional increase of 0.0847 billion shares. Its 1-year return is 4.62%, and the 3-year return is 4.32% (ranked 45/329) [21]. Mixed Bond - Type II Funds - E Fund Yuxiang Return A (002351.OF) has a scale of 2.6613 billion yuan, an institutional holding of 1.5665 billion shares, and an institutional increase of 0.1322 billion shares. Its 1-year return is 5.42% (ranked 173/507), and the 3-year return is 3.05% (ranked 76/340) [21]. - Invesco Great Wall Jingsheng Double Dividend A (002065.OF) has a scale of 1.1558 billion yuan, an institutional holding of 0.9907 billion shares, and an institutional increase of 0.2778 billion shares. Its 1-year return is 4.20% (ranked 265/507), and the 3-year return is 4.49% (ranked 11/340) [21]. Partial - Bond Hybrid Funds - E Fund Hengsheng 3 - Month Fixed - Open (007884.OF) has a scale of 0.2021 billion yuan, an institutional holding of 0.1734 billion shares, and no institutional increase. Its 1-year return is 8.71% (ranked 117/674), and the 3-year return is 5.36% (ranked 15/587) [21]. - Anxin Minwen Growth A (008809.OF) has a scale of 0.3115 billion yuan, an institutional holding of 0.1198 billion shares, and an institutional decrease of 0.0067 billion shares. Its 1-year return is 7.60% (ranked 169/674), and the 3-year return is 4.33% (ranked 41/587) [21]. Flexible Allocation - Partial - Bond Funds - Boshi Hongkang A (003411.OF) has a scale of 0.3552 billion yuan, an institutional holding of 0.1264 billion shares, and an institutional increase of 0.0177 billion shares. Its 1-year return is 1.64% (ranked 127/139), and the 3-year return is 2.60% (ranked 40/139) [21]. - E Fund Ruicai I (001802.OF) has a scale of 0.1288 billion yuan, an institutional holding of 0.1088 billion shares, and no institutional increase. Its 1-year return is 9.31% (ranked 10/139), and the 3-year return is 4.79% (ranked 5/139) [21]. Convertible Bond - Style Funds - Huatai Baoxing Zunli A (005908.OF) has a scale of 0.7893 billion yuan, an institutional holding of 0.5427 billion shares, and an institutional increase of 0.0791 billion shares. Its 1-year return is 12.89% (ranked 45/102), and the 3-year return is 6.77% (ranked 4/102) [21]. - Huashang Credit Enhancement A (001751.OF) has a scale of 0.7591 billion yuan, an institutional holding of 0.3941 billion shares, and an institutional increase of 0.0952 billion shares. Its 1-year return is 22.38% (ranked 9/102), and the 3-year return is 5.17% (ranked 13/102) [21]. Convertible Bond - Type Funds - China - Europe Convertible Bond A (004993.OF) has a scale of 0.7529 billion yuan, an institutional holding of 0.511 billion shares, and an institutional increase of 0.2871 billion shares. Its 1-year return is 20.92% (ranked 1/39), and the 3-year return is - 2.06% (ranked 22/39) [21]. - Penghua Convertible Bond A (000297.OF) has a scale of 0.635 billion yuan, an institutional holding of 0.4305 billion shares, and an institutional decrease of 0.0113 billion shares. Its 1-year return is 12.89% (ranked 17/39), and the 3-year return is - 2.84% (ranked 26/39) [21].

Investment Rating - The report maintains a "Buy" rating for the company, with expected earnings per share (EPS) of 5.46, 6.06, and 6.78 yuan for the years 2025, 2026, and 2027 respectively, corresponding to price-to-earnings (P/E) ratios of 21, 19, and 17 times [4]. Core Insights - The company reported a slight decrease in revenue of 0.54% year-on-year for the first half of 2025, totaling 6.603 billion yuan, while net profit attributable to shareholders fell by 42.85% to 983 million yuan [2]. - The core subsidiary, Jinsai Pharmaceutical, achieved revenue growth of 6.17% year-on-year, amounting to 5.469 billion yuan, but net profit decreased by 37.35% to 1.108 billion yuan [2]. - The company has significantly increased its R&D investment, reaching 1.335 billion yuan, a 17.32% increase year-on-year, which now constitutes 20.21% of its revenue [2]. Revenue and Profit Analysis - For the second quarter of 2025, the company reported revenue of 3.605 billion yuan, a year-on-year increase of 4.16%, while net profit attributable to shareholders decreased by 40.75% to 510 million yuan [2]. - The report forecasts a decline in net profit for 2025 to 2.225 billion yuan, a 13.85% decrease from the previous year, with a gradual recovery expected in subsequent years [4]. R&D and Product Development - Jinsai Pharmaceutical is focusing on innovative treatments in various therapeutic areas, including immunology and oncology, with new products like the IL-1β monoclonal antibody and GenSci120 injection entering clinical trials [3]. - The company is actively enhancing its R&D capabilities and talent acquisition to support the development of new products, which is reflected in the increased R&D expenses [2][3]. Financial Projections - The company is expected to achieve net profits of 2.225 billion yuan in 2025, 2.471 billion yuan in 2026, and 2.766 billion yuan in 2027, with corresponding EPS of 5.455, 6.056, and 6.779 yuan [4]. - The projected revenue for 2025 is 12.364 billion yuan, reflecting a decline of 8.18% from the previous year, with a gradual recovery anticipated in the following years [9].

Investment Rating - The report establishes a positive investment outlook for the wind power sector, indicating a confirmed industry turning point in H1 2025, with expectations for continued revenue and profit growth [3]. Core Insights - The wind power sector achieved revenue of CNY 1,047 billion in H1 2025, representing a year-on-year increase of 45.6%, and a net profit of CNY 42.3 billion, up 15.5% year-on-year [2][21]. - The report highlights a significant increase in demand driven by the "531 rush installation," with new wind power installations reaching 51.4 GW in H1 2025, a 99% increase year-on-year [7]. - The report anticipates sustained high demand in H2 2025 and FY 2026, supported by a robust order backlog of approximately 300 GW across leading manufacturers [2][12]. Summary by Sections Revenue and Profit Growth - The wind power sector's revenue and profit growth in H1 2025 was driven by strong demand, with Q2 2025 revenue reaching CNY 664 billion, a 52.4% increase year-on-year, marking the highest quarterly revenue in nearly 23 years [2][24]. - The overall gross margin and net margin for the industry showed a decline due to the increased proportion of lower-margin manufacturing revenue [2][21]. Order Backlog and Future Demand - As of the end of H1 2025, leading manufacturers maintained a growing order backlog, sufficient to cover the next two years of installation demand, indicating a positive outlook for 2026 [12][21]. - The report notes that the average bidding price for wind turbines has been increasing, with a notable rise in the average price for various power segments [14][16]. Segment Performance - The report identifies three key investment themes: 1. The turbine manufacturing segment benefiting from domestic demand and price increases, with recommended stocks including Goldwind Technology, Yunda Co., and Mingyang Smart Energy [3]. 2. The submarine cable and foundation segments benefiting from high demand and overseas orders, with recommendations for companies like Daikin Heavy Industries and Oriental Cable [3]. 3. The forging and casting segments showing significant profit elasticity due to supply-demand tightness, with recommended stocks including Jinlei Co. and Riyue Co. [3]. Cost and Margin Analysis - The report indicates that the cost structure across various segments has improved, with a decrease in expense ratios due to higher revenue growth, particularly in the casting and forging segments [41][42]. - The gross margins for the turbine manufacturing segment have been under pressure, but segments like casting and blades have shown recovery in profitability [38][39].

Investment Rating - The report indicates a cautious outlook for the consumer goods sector, with specific recommendations for companies that demonstrate resilience and growth potential in challenging market conditions [2][4]. Core Insights - The consumer goods sector is experiencing pressure on overall demand and intensified market competition, characterized by declining prices, slow product structure upgrades, and increased costs for acquiring potential customers [2][3]. - Despite the overall challenges, certain companies are performing well, particularly those with strong brand positioning and innovative product offerings, such as salt and pepper products and energy drinks [2][4]. - The report highlights two main investment themes: companies with solid fundamentals and growth potential in the next 2-3 years, and those that may benefit from a recovery in demand across various segments [5][31]. Summary by Sections 1. Snack Foods - The snack food segment shows a divergence in performance, with leading brands like Salted Fish and Wei Long achieving significant revenue growth, while others face challenges due to channel shifts and lower consumer spending [3][12]. - The report notes that the market is transitioning from channel-driven growth to category-driven growth, with health-oriented products gaining traction [12][19]. 2. Restaurant Chains - The restaurant chain segment is under pressure, with major players like Hai Tian and Zhong Ju experiencing varied revenue growth rates, reflecting the competitive landscape and changing consumer preferences [4][34]. - The report emphasizes the importance of adapting to consumer trends, such as the increasing demand for healthy and convenient food options [33][34]. 3. Soft Drinks - The soft drink sector is witnessing improved sales during peak seasons, with health-focused products like sugar-free tea and electrolyte drinks gaining market share [4][12]. - Companies like Nongfu Spring and Dongpeng are highlighted for their strong performance, with significant revenue increases reported [4][12]. 4. Dairy Products - The dairy segment is facing challenges, particularly in liquid milk demand, but cost advantages are noted for certain products, leading to improved profit margins for some companies [5][29]. - The report suggests that companies with diversified product lines and effective cost management strategies are better positioned to navigate the current market conditions [5][29].

Investment Rating - The report suggests a positive outlook for the medical device industry, indicating that the adjustment period is nearing its end and a recovery is expected in the second half of 2025 [2][4]. Core Insights - The medical device sector is experiencing a recovery trend, with domestic bidding demand showing signs of restoration in the second half of 2025 after a significant decline due to policy delays [2]. - The medical consumables segment is steadily growing, with a slight increase in gross margin, indicating resilience in demand related to patient treatment needs [2]. - The in-vitro diagnostics sector is under pressure, but there is potential for increased domestic market share for local manufacturers in the long term [2]. - Leading medical device companies are accelerating their overseas market expansion, with many reporting higher growth rates in international markets compared to domestic ones [2]. Summary by Sections Medical Equipment - Revenue for Q2 2025 showed a year-on-year decline of 5.26%, with net profit down 27.93% and gross margin decreasing from 53.07% in Q2 2024 to 49.00% in Q2 2025 [16]. - The industry is expected to reach a turning point as domestic bidding demand recovers [2][18]. Medical Consumables - Q2 2025 revenue increased by 1.33% year-on-year, with net profit down 6.28% and a slight improvement in gross margin from 42.13% to 42.24% [23]. - The segment is characterized by stable growth, with companies focusing more on R&D and innovative products [2]. In-Vitro Diagnostics - Revenue for Q2 2025 decreased by 16.53% year-on-year, with net profit down 37.58% and gross margin declining from 62.43% to 59.66% [29]. - The sector faces short-term demand pressure but may benefit from increased domestic production rates in the long run [2]. Investment Recommendations - The report recommends focusing on three key areas: companies leading in international market product and channel expansion, domestic medical device industry leaders, and high-value consumables firms with strong innovation capabilities [34]. - Specific companies to watch include Nanwei Medical, Mindray Medical, Sanofi, and Xinjiang Technology [34].

Investment Rating - The report indicates a recovery in the military industry, particularly in missile and military electronics sectors, suggesting a positive investment outlook for the industry [1][3]. Core Insights - The military industry is actively preparing for production in the first half of 2025, with revenue recovery observed in Q2. The electronic information sector is experiencing alleviated pricing pressures, while the aviation sector is expected to accelerate deliveries in the second half of the year [3][4][14]. - The overall revenue for the military industry in the first half of 2025 was 227.8 billion, a decrease of 6.7% year-on-year, but a recovery of 3.3% in Q2 compared to the previous quarter [6][7]. - The net profit attributable to shareholders for the first half of 2025 was 14.3 billion, down 28.0% year-on-year, but showing a significant recovery of 84.5% in Q2 compared to Q1 [6][7]. Summary by Sections Overall Industry Performance - The military industry is seeing a significant increase in contract liabilities compared to the beginning of the year, indicating a recovery in the upstream revenue sector in Q2 2025 [11][27]. - The first half of 2025 saw a gross margin of 22.1%, a slight decrease of 0.2 percentage points year-on-year, while the net margin was 6.3%, down 1.9 percentage points year-on-year [6][19]. Segment Performance - In the electronic information sector, revenue reached 38.2 billion, with an 8.7% year-on-year increase, while net profit was 2.93 billion, down 2.1% year-on-year [16][19]. - The aviation sector reported revenue of 146.9 billion, a decrease of 12.9% year-on-year, with net profit down 33.4% [16][19]. - The weaponry sector showed a revenue increase of 26.0% year-on-year, with net profit down 6.4% [16][19]. Industry Chain Insights - The downstream sector's contract liabilities increased significantly, reflecting a recovery in the upstream revenue sector in Q2 2025 [27][34]. - The gross margin for the upstream sector was 34.9%, down 2.9 percentage points year-on-year, while the net margin was 12.8%, down 3.9 percentage points [29][30].

Investment Rating - The report suggests a positive outlook for the military industry, indicating a recovery in the sector with a recommendation to focus on military trade, new combat capabilities, consumable ammunition, and military electronics as key investment themes [2][3]. Core Insights - The military industry showed signs of recovery in H1 2025, with revenues reaching 227.8 billion yuan, a year-on-year decrease of 6.7%, and a net profit of 14.3 billion yuan, down 28.0% year-on-year. The second quarter of 2025 saw revenues of 140.2 billion yuan, an increase of 3.3% year-on-year, and a net profit of 9.3 billion yuan, down 23.4% year-on-year [2][7]. - The aerospace sector experienced a revenue decline of 12.9% in H1 2025, while the weaponry sector saw a revenue increase of 26.0%. The missile and military electronics sectors showed significant improvement, with military electronics revenues in Q2 2025 reaching 17.9 billion yuan, up 18.8% year-on-year [2][3][17]. - The report emphasizes that 2025 is a critical year for the military industry, driven by multiple factors including the end of the 14th Five-Year Plan and the beginning of the 15th Five-Year Plan, as well as a global arms race, which may lead to a revaluation of military assets in China [2][3]. Summary by Sections Overall Industry Performance - In H1 2025, the military industry actively prepared for production, with Q2 revenues showing recovery. The electronic information sector faced reduced pricing pressure, while the aerospace sector is expected to accelerate deliveries in the second half of the year [3][26]. - The downstream contract liabilities increased significantly compared to the beginning of the year, indicating a recovery in the upstream revenue sector in Q2 2025 [3][26]. Key Segments Performance - The electronic information sector reported revenues of 38.2 billion yuan in H1 2025, up 8.7% year-on-year, while the aerospace sector's revenues were 146.9 billion yuan, down 12.9% year-on-year. The weaponry sector's revenues increased by 26.0% [17][20]. - The report highlights that the missile industry chain's revenues in Q2 2025 reached 5.2 billion yuan, up 21.5% year-on-year, indicating a narrowing decline in net profit [2][3][17]. Financial Metrics - The overall gross margin for the military industry in H1 2025 was 22.1%, a slight decrease of 0.2 percentage points year-on-year, while the net margin was 6.3%, down 1.9 percentage points year-on-year [7][20]. - The report provides detailed financial metrics for various segments, indicating that the electronic information sector had a gross margin of 42.6% in H1 2025, while the aerospace sector had a gross margin of 17.6% [20][28].